The U.S. CDC's Advisory Committee recommends the use of GSK's pentavalent Penmenvy vaccine as part of the adolescent ...

GSK plc (LSE/NYSE: GSK) today announced that the US Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) has voted to recommend use of PENMENVY ...

GSK’s five-in-one meningococcal vaccine has been recommended by the US Centers for Disease Control and Prevention’s (CDC) ...

Vaccine recommended to help protect persons over 10 years old in the United States ... Please consult the full Prescribing Information for additional safety information. Important Safety Information ...

Vaccine recommended to help protect persons ... Important Safety Information for MENVEO in the US The following is based on the US Prescribing Information for MENVEO. Please consult the full ...

with a safety profile consistent with Bexsero and Menveo. GSK’s chief scientific officer, Tony Wood, said that the results show the vaccine protects against “the broadest panel of circulating ...

The new vaccine is a combination of GSK’s already-approved vaccines Bexsero and Menveo and is designed to protect against meningitis and blood poisoning caused by the A, B, C, W, and Y ...

Penmenvy combines the antigenic components of Bexsero (meningococcal Group B vaccine) and Menveo (meningococcal Groups A, C, Y, and W-135 oligosaccharide diphtheria CRM197 conjugate vaccine).

Penmenvy 可预防脑膜炎球菌血清型 A、B、C、W 和 Y。一种疫苗可广泛覆盖血清群，减少注射次数，有助于提高疫苗接种率，保护更多美国青少年和年轻人。 葛兰素史克公司 (LSE/NYSE: GSK) 宣布，美国食品药品监督管理局 (FDA) ...